Intellia Therapeutics (NTLA) Reports Q4 Loss of $0.31/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 falls from record high as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Intellia Therapeutics Announces Fourth Quarter and Full-Year 2016 Financial Results
March 14, 2017 7:15 AM EDTFirst to demonstrate single dose, in vivo results, showing approximately 97 percent reduction in serum transthyretin protein levelsFurther established a comprehensive platform, including a proprietary lipid nanoparticle delivery system, to accelerate therapeutic developmentExecuted partnering deal with Regeneron Pharmaceuticals, and continued to advance Intellias partnership with Novartis, to support Intellias emerging pipeline with six distinct programs in active research and development, spanning multiple types of genome editingContinued to deploy a diversified approach to maximize CRISPR potential, including pursuing CRISPR... More
